Phase 2 trial of oxaliplatin and pemetrexed as an induction regimen in locally advanced head and neck cancer

Cancer

Volumn 118, Issue 4, 2012, Pages 1007-1013

  Gilbert, Jill ^a   Murphy, Barbara ^a   Dietrich, Mary S ^a,b   Henry, Eve ^a   Jordan, Richard ^c,d   Counsell, Ashley ^a   Wirth, Pamela ^a   Yarbrough, Wendell G ^a   Slebos, Robert J ^a   Chung, Christine H ^a,e  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

head and neck cancer; HPV; oxaliplatin; pemetrexed; phase 2

Indexed keywords

OXALIPLATIN; PEMETREXED; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DNA;

ACIDOSIS; ADULT; ADVANCED CANCER; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CORRELATIONAL STUDY; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GENE EXPRESSION; HEAD AND NECK CANCER; HUMAN; HUMAN TISSUE; HYPERTRANSAMINASEMIA; HYPOKALEMIA; INFECTION; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; SEPSIS; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; TUMOR VOLUME; VIRUS DETECTION; AGED; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA REPAIR; DRUG DOSE REDUCTION; FEBRILE NEUTROPENIA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN CELL; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; WART VIRUS;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; FEMALE; GLUTAMATES; GUANINE; HEAD AND NECK NEOPLASMS; HUMANS; INDUCTION CHEMOTHERAPY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; OUTCOME ASSESSMENT (HEALTH CARE); SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84856805559     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26364     Document Type: Article

References (11)

1. Pointreau Y, Garaud P, Chapet S, et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst. 2009; 101: 498-506.
2. Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007; 357: 1705-1715.
3. Zorat PL, Paccagnella A, Cavaniglia G, et al. Randomized phase III trial of neoadjuvant chemotherapy in head and neck cancer: 10-year follow-up. J Natl Cancer Inst. 2004; 96: 1714-1717.
4. Slebos RJ, Yi Y, Ely K, et al. Gene expression differences associated with human papillomavirus status in head and neck squamous cell carcinoma. Clin Cancer Res. 2006; 12: 701-709.
5. Baumann JL, Cohen S, Evjen AN, et al. Human papillomavirus in early laryngeal carcinoma. Laryngoscope. 2009; 119: 1531-1537.
6. Tusher VG, Tibshirani R, Chu G,. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A. 2001; 98: 5116-5121.
7. Eisen MB, Spellman PT, Brown PO, et al. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A. 1998; 95: 14863-14868.
8. Chung CH, Parker J, Levy S,. Gene expression profiles as markers of aggressive diseaseâEGFR as a factor. Int J Radiat Oncol Biol Phys. 2007; 69: S102-S105.
9. Simon R,. Optimal 2-stage designs for phase II clinical trials. Control Clin Trials. 1989; 10: 1-10.
10. Cho JM, Manandhar S, Lee HR, et al. Role of the Nrf2-antioxidant system in cytotoxicity mediated by anticancer cisplatin: implication to cancer cell resistance. Cancer Lett. 2008; 260: 96-108.
11. zur Hausen H,. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst. 2000; 92: 690-698.